Elagolix in the treatment of endometriosis: impact beyond pain symptoms

  • Archer D
  • Soliman A
  • Agarwal S
  • et al.
N/ACitations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

While the most common symptom associated with endometriosis is pelvic pain, the systemic manifestations of the disease and the accompanying adverse psychological, emotional, social, familial, sexual, educational and workplace effects are increasingly recognized. Elagolix is an oral gonadotropin-releasing hormone receptor antagonist that is approved for the management of moderate to severe pain associated with endometriosis. However, the benefits of elagolix extend beyond reducing pain symptoms. This article reviews the non-pain systemic manifestations associated with endometriosis and summarizes the beneficial effects of elagolix on non-pain outcomes. This includes improvements in quality of life, reductions in fatigue and improvements in workplace and household productivity. These results indicate that elagolix provides non-pain benefits in women with endometriosis and improves outcomes that are clinically meaningful to patients.

Cite

CITATION STYLE

APA

Archer, D. F., Soliman, A. M., Agarwal, S. K., & Taylor, H. S. (2020). Elagolix in the treatment of endometriosis: impact beyond pain symptoms. Therapeutic Advances in Reproductive Health, 14, 263349412096451. https://doi.org/10.1177/2633494120964517

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free